Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis to launch...

    Novartis to launch epinephrine-rival to EpiPens

    Farhat NasimWritten by Farhat Nasim Published On 2018-12-07T09:30:06+05:30  |  Updated On 17 Aug 2021 10:35 AM IST

    New Delhi: Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 per cent below that of similar rival products.


    Sandoz will start selling the pre-filled epinephrine syringes, SYMJEPI, in the United States in the first quarter of 2019 at a wholesale price of $250 for a two-pack of 0.3 mg injections, Novartis said in a statement.


    Mylan dominates the market with its EpiPens, auto-injectors that deliver a dose of epinephrine in the event of a severe allergic reaction, such as to bee stings or exposure to peanuts.


    There has been a shortage of EpiPens in North America, Europe and Canada this year due to manufacturing delays. The U.S. Food and Drug Administration in May added the treatment to its list of drugs in shortage.


    In November, Teva Pharmaceutical Industries Ltd launched its generic version of the EpiPen at the wholesale price of $300 for a pack of two auto-injectors - the same price as Mylan's generic version of its own shot.


    Adamis, which received U.S. approval for its emergency epinephrine syringes in 2017, will distribute SYMJEPI in the United States exclusively through Sandoz.


    In a separate statement earlier on Thursday, Adamis said that the manufacturing of SYMJEPI's commercial batches was complete, and it would begin shipping to distribution centres in December.


    Mylan's EpiPen sales practices in the United States sparked public outrage in 2016 as consumers saw the price for a pack of two auto-injectors rise six-fold to $600 in less than a decade, making the devices unaffordable for a growing number of families.


    Mylan launched its generic at around half that list price in late 2016.


    Also Read: Novartis India Managing Director Milan Paleja quits
    Adamis Pharmaceuticalsepinephrine syringesEpiPensMylanNovartisNovartis AGSandozSYMJEPITeva PharmaceuticalUnited StatesUS Food and Drug Administration
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok